What “Research Use Only” Does and Does Not Protect

Here is the position FDA itself has now stated in enforcement letters: a "research use only" label does not decide what your product is. Your marketing does. On December 10, 2024, FDA issued warning letters to a group of online peptide sellers, and the letters address the research-only framing directly, which makes them the closest thing this industry has to a written answer on where the line sits.

What the December 2024 letters say

The letters, including those to Summit Research Peptides and Prime Vitality, doing business as Prime Peptides, concern peptide products including semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide offered for sale online. FDA's charge is that these are unapproved new drugs introduced into interstate commerce, in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.

The part that matters for everyone else in the category is how FDA handled the disclaimers. The products carried labeling stating they were for research purposes only and not for human consumption or clinical use. FDA's letters say that evidence obtained from the sellers' own websites established that the products were intended for use as drugs in people. The disclaimer said one thing; the marketing, in FDA's reading, said another; and FDA went with the marketing.

The doctrine underneath: intended use

None of this is novel law. How a product is classified turns substantially on its intended use, and intended use is read from the totality of how the product is presented: product pages, category names, blog posts, testimonials, imagery, social content, even the search terms a site optimizes for. A bottle that says research only sitting on a page that speaks to human outcomes is, in the agency's eyes, a human-use product with a decorative label.

That is why this topic belongs in an SEO firm's library. The evidence FDA cited was website content. The marketing is not adjacent to the compliance question, it is the compliance question. Every page a peptide seller publishes is a statement of intended use that a regulator can read, and increasingly does.

What follows for content, concretely

We are not lawyers and this is not legal advice; product classification questions belong with regulatory counsel. What we can describe is the content discipline that follows from FDA's stated reasoning:

• Consistency is the whole game. A disclaimer contradicted anywhere on the site is worse than no disclaimer, because it documents that you knew the line and stepped over it.
• Outcome language is intent evidence. Copy that describes what a compound does in people, on any page, undercuts a research-only position everywhere.
• Keywords are content. Optimizing for queries that are explicitly about human use tells the same story to a regulator that it tells to Google.
• Testimonials and user-generated content count too. FDA letters across categories have long treated them as claims by the seller.

There is also a platform dimension. Google's ads policy reaches products "subject to any government or regulatory action or warning", so enforcement letters in a product category tighten the paid-channel exclusion we describe in the ads-policy article. And in organic search, sites in a category under enforcement attention are exactly the sites Google's quality systems examine hardest, which is where sourced, precise, honestly framed content stops being a legal nicety and becomes a ranking strategy.

The honest summary is uncomfortable but useful: the phrase research use only protects nothing by itself. What does the work is a marketing operation that actually matches it, everywhere, on every page, in every keyword. Companies that want the label without the discipline are the ones the December letters were addressed to.

Frequently asked questions